| Knowledge-base field | Curated summary | Ontology / representative data | Evidence |
|---|---|---|---|
| Identity and identifiers | Buschke–Ollendorff syndrome (BOS) is a rare Mendelian genodermatosis and sclerosing bone dysplasia defined by connective-tissue nevi with osteopoikilosis. Melorheostosis may coexist, but sporadic melorheostosis is genetically distinct. Synonyms include dermatofibrosis lenticularis disseminata with osteopoikilosis and dermato-osteopoikilosis. | MONDO:0008157; OMIM/MIM 166700 | (pqac-00000002, pqac-00000003, pqac-00000004) |
| Defining phenotype | Usually asymmetrical, non-tender, flesh-colored to yellow papules, nodules, or cobblestone plaques representing elastoma, collagenoma, or mixed connective-tissue nevi. Radiographs show multiple small, round or ovoid, generally symmetric periarticular sclerotic bone islands, especially in epiphyses, metaphyses, pelvis, carpal bones, and tarsal bones. | Suggested HPO: Connective tissue nevus; Collagenoma; Osteopoikilosis (HP:0005681); Melorheostosis (HP:0005781); Arthralgia (HP:0002829); Joint contracture (HP:0001371) | (pqac-00000002, pqac-00000005, pqac-00000008) |
| Causal gene and inheritance | Heterozygous germline loss-of-function variants in **LEMD3** (MAN1) cause autosomal-dominant BOS through haploinsufficiency. Expression is highly variable within families, and not every clinically affected family has an identifiable coding variant. No reliable genotype–phenotype correlation is established. | **LEMD3**; ENSG00000174106. Representative variants: c.1323C>A, p.Tyr441Ter; c.332_333insTC; c.1863G>A, p.Trp621Ter; c.2203C>T, p.Arg735Ter. Reported classes include nonsense, frameshift, splice-disrupting, and larger deletion variants. | (pqac-00000000, pqac-00000001, pqac-00000002, pqac-00000007) |
| Mechanism | MAN1 is an integral inner-nuclear-membrane protein whose C-terminal region binds receptor-regulated SMADs. Loss of MAN1-mediated antagonism increases BMP and TGF-β/activin signaling. This plausibly promotes abnormal dermal extracellular-matrix accumulation and focal osteogenesis. Human bone biopsies support activation of bone-lining cells and modeling-based formation of compact lamellar bone, although the complete tissue-selective causal chain remains unresolved. | Suggested GO: inner nuclear membrane (GO:0005637); BMP signaling pathway (GO:0030509); TGF-β receptor signaling pathway (GO:0007179); SMAD protein signal transduction (GO:0060395); ossification (GO:0001503); extracellular-matrix organization (GO:0030198). Suggested CL: fibroblast (CL:0000057); osteoblast (CL:0000062). | (pqac-00000003, pqac-00000013, pqac-00000015) |
| Onset and course | Connective-tissue nevi most often begin congenitally, in infancy, or during childhood, but delayed adult presentation occurs. Lesions may enlarge slowly. Osteopoikilosis is developmental, persistent, and commonly detected incidentally. Severity ranges from asymptomatic disease to uncommon pain, contracture, deformity, or restricted motion. | Suggested HPO onset: Congenital onset (HP:0003577); Infantile onset (HP:0003593); Childhood onset (HP:0011463). Course: chronic and usually stable or slowly progressive. | (pqac-00000002, pqac-00000004, pqac-00000008) |
| Diagnosis | Diagnosis integrates dermatologic examination, characteristic plain radiographs, family history, and, when needed, skin biopsy and germline **LEMD3** sequencing with deletion/duplication analysis. Histology may show thick disorganized elastic fibers, dense collagen bundles, mixed lesions, or mucin. Important differentials include isolated osteopoikilosis, osteoblastic metastases, mastocytosis, tuberous-sclerosis shagreen patch, familial or eruptive collagenoma, papular elastorrhexis, morphea, and melorheostosis. | Genetic marker: pathogenic or likely pathogenic germline **LEMD3** variant. Suggested procedures: radiography; skin biopsy; sequence analysis; copy-number analysis. | (pqac-00000005, pqac-00000008, pqac-00000010, pqac-00000016) |
| Epidemiology | Frequently cited occurrence is approximately 1 in 20,000, but this is an estimate rather than a robust population-registry measurement. BOS-specific incidence, sex ratio, ethnic differences, carrier frequency, and geographic variation remain undetermined. | Rare disease; no validated population-stratified prevalence dataset | (pqac-00000005, pqac-00000006, pqac-00000008) |
| Treatment and prognosis | No disease-modifying or genotype-directed therapy is established. Most asymptomatic patients require reassurance and observation. Management is individualized and may include analgesia or physical therapy for musculoskeletal symptoms, dermatologic procedures for troublesome nevi, and orthopedic intervention for substantial deformity, contracture, or impingement. Prognosis and life expectancy are generally normal because typical osteopoikilosis and skin lesions are benign. | Suggested NCIT intervention concepts: Observation; Genetic Counseling; Analgesic Therapy; Physical Therapy; Surgical Procedure | (pqac-00000005, pqac-00000012, pqac-00000014) |
| Evidence gaps | No validated protective or environmental risk factors, gene–environment interaction, epigenomic signature, circulating biomarker, formal staging system, disease-specific quality-of-life instrument, pharmacogenomic guidance, approved targeted therapy, or relevant interventional clinical trial was identified. No faithful animal model recapitulates the combined human skin-and-bone phenotype. Inconsistent fibroblast signaling and absent genotype–phenotype correlation limit mechanistic prediction. | Research priorities: longitudinal natural-history registry; standardized phenotyping; lesional single-cell and spatial profiling; functional variant assays; tissue-specific models | (pqac-00000011, pqac-00000012, pqac-00000013) |


*Table: A knowledge-base-ready synopsis of BOS identity, phenotype, genetics, mechanism, diagnosis, course, management, and major evidence gaps, with ontology suggestions and representative LEMD3 variants.*